Mylan off the hook for $50 million tax bill for patent expenses
US appellate court confirms IRS may no longer deny generic drugmakers the ability to deduct ANDA litigation costs
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.